Andrew Witty, the former CEO of GlaxoSmithKline, is a British businessman with an estimated net worth of 225 million as of 2023. He led the company from 2008 to 2017, during which time he oversaw its transformation into a global healthcare leader.
Witty’s wealth stems from his successful career in the pharmaceutical industry. He joined GlaxoSmithKline in 1985 and held various senior positions before becoming CEO. Under his leadership, the company developed and launched several blockbuster drugs, including Advair, Avandia, and Paxil. He also led the acquisition of several smaller companies, which helped to expand GlaxoSmithKline’s portfolio of products.
